NextPlat (NXPL) Cash from Investing Activities (2010 - 2025)
NextPlat's (NXPL) quarterly Cash from Investing Activities came in at -$37000.0 in Q4 2025, down 232.14% year-over-year from $28000.0 in Q4 2024, and down 136.27% quarter-over-quarter from $102000.0 in Q3 2025.
Powered by 
Analysis
NextPlat (NXPL) Cash from Investing Activities (2010 - 2025) Analysis & Trends
NextPlat (NXPL) has reported Cash from Investing Activities for 12 consecutive years, with -$37000.0 the latest figure, recorded in Q4 2025.
- On a quarterly basis, Cash from Investing Activities fell 232.14% year-over-year to -$37000.0 in Q4 2025; TTM through Jun 2026 was $65000.0, a 48.41% decrease from a year earlier, with the FY2025 full-year figure at $163000.0, up 117.1% from the prior year.
- Cash from Investing Activities was -$37000.0 for Q4 2025 at NextPlat, down from $102000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $6.5 million in Q3 2023 and troughed at -$7.1 million in Q3 2022.
- A 5-year average of -$186121.4 and a median of -$67997.0 in 2022 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities slumped 14714.16% in 2022 and jumped 191.73% in 2023, its largest moves.
- Over 5 years, Cash from Investing Activities stood at -$133709.0 in 2021, then slumped by 83.15% to -$244882.0 in 2022, then rose by 22.82% to -$189000.0 in 2023, then surged by 114.81% to $28000.0 in 2024, then slumped by 232.14% to -$37000.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$37000.0 (Q4 2025), $102000.0 (Q3 2025), and $120000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | -491.00 Mn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | -51.60 Mn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 40.52 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | -122.74 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | -93.00 Mn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | -3.05 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | -44.77 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 44.87 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | - |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -37,000.00 |
| Sep 30, 2025 | 102,000.00 |
| Jun 30, 2025 | 120,000.00 |
| Mar 31, 2025 | -22,000.00 |
| Dec 31, 2024 | 28,000.00 |
| Jun 30, 2024 | -918,000.00 |
| Mar 31, 2024 | -63,000.00 |
| Dec 31, 2023 | -189,000.00 |
| Sep 30, 2023 | 6.49 Mn |
| Jun 30, 2023 | -1.03 Mn |
| Mar 31, 2023 | -69,000.00 |
| Dec 31, 2022 | -244,882.00 |
| Sep 30, 2022 | -7.08 Mn |
| Jun 30, 2022 | -327,248.00 |
| Mar 31, 2022 | -67,997.00 |
| Dec 31, 2021 | -133,709.00 |
| Sep 30, 2021 | -68,350.00 |
| Jun 30, 2021 | -26,789.00 |
| Mar 31, 2021 | -459.00 |
| Dec 31, 2020 | -4,151.00 |